A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience.
Chantal PauliTilmann BochtlerLinda MileshkinGiulia BaciarelloFerran LosaJeffrey S RossGeorge PentheroudakisGeorge ZarkavelisSuayib YalcinMustafa ÖzgüroğluAndreas BeringerJeremy ScaratoMathis Mueller-OhldachMarlene ThomasHolger MochAlwin KrämerPublished in: The oncologist (2021)
A high unmet need exists for improved treatment of cancer of unknown primary (CUP); however, study in a trial setting is faced with the significant challenge of definitively distinguishing CUP from other cancer types. This article reports the authors' experience of this challenge so far in the ongoing CUPISCO trial, which compares treatments guided by patients' unique genetic signatures versus standard chemotherapy. The data presented will aid future decision-making regarding diagnosing true CUP cases; this will have far-reaching implications in the design, execution, and interpretation of not only CUPISCO but also future clinical studies aiming to find much-needed treatment strategies.
Keyphrases
- phase iii
- study protocol
- papillary thyroid
- phase ii
- clinical trial
- decision making
- end stage renal disease
- squamous cell
- newly diagnosed
- ejection fraction
- current status
- chronic kidney disease
- randomized controlled trial
- open label
- prognostic factors
- electronic health record
- gene expression
- radiation therapy
- lymph node metastasis
- childhood cancer
- patient reported
- double blind
- drug induced